drugset / Trial / NCT05566574
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Phase 1/2
Active not recruiting
49 enrolled
Memorial Sloan Kettering Cancer Center
Repare Therapeutics · collab
NaParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camonsertib | Small molecule | 80 mg | — |